Fredun Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Fredun Pharmaceuticals CEO'su Daulat Medhora, Jan2010 tarihinde atandı, in görev süresi 14.83 yıldır. in toplam yıllık tazminatı ₹ 1.20M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 30.02% ine doğrudan sahiptir ve bu hisseler ₹ 950.52M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.1 yıl ve 9.2 yıldır.

Anahtar bilgiler

Daulat Medhora

İcra Kurulu Başkanı

₹1.2m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	14.8yrs
CEO sahipliği	30.0%
Yönetim ortalama görev süresi	10.1yrs
Yönetim Kurulu ortalama görev süresi	9.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Daulat Medhora'un ücretlendirmesi Fredun Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹177m
Jun 30 2024	n/a	n/a	₹174m
Mar 31 2024	₹1m	₹1m	₹156m
Dec 31 2023	n/a	n/a	₹183m
Sep 30 2023	n/a	n/a	₹130m
Jun 30 2023	n/a	n/a	₹123m
Mar 31 2023	₹1m	₹1m	₹108m
Dec 31 2022	n/a	n/a	₹58m
Sep 30 2022	n/a	n/a	₹83m
Jun 30 2022	n/a	n/a	₹70m
Mar 31 2022	₹1m	₹1m	₹63m
Dec 31 2021	n/a	n/a	₹39m
Sep 30 2021	n/a	n/a	₹33m
Jun 30 2021	n/a	n/a	₹23m
Mar 31 2021	₹1m	n/a	₹20m
Dec 31 2020	n/a	n/a	₹20m
Sep 30 2020	n/a	n/a	₹17m
Jun 30 2020	n/a	n/a	₹17m
Mar 31 2020	₹1m	₹1m	₹19m
Dec 31 2019	n/a	n/a	₹32m
Sep 30 2019	n/a	n/a	₹39m
Jun 30 2019	n/a	n/a	₹53m
Mar 31 2019	n/a	n/a	₹45m
Dec 31 2018	n/a	n/a	₹41m
Sep 30 2018	n/a	n/a	₹26m
Jun 30 2018	n/a	n/a	₹8m
Mar 31 2018	₹1m	₹1m	₹18m

Tazminat ve Piyasa: Daulat 'nin toplam tazminatı ($USD 14.21K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 42.63K ).

Tazminat ve Kazançlar: Daulat 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Daulat Medhora (79 yo)

14.8yrs

Görev süresi

₹1,200,000

Tazminat

Dr. Daulat N. Medhora serves as Executive Chairman and Joint Managing Director of Fredun Pharmaceuticals Limited since January 01, 2010 and has been its Director since June 08, 1987. Dr. Medhora holds PhD...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daulat Medhora	Executive Chairman & Joint MD	14.8yrs	₹1.20m	30.02% ₹ 950.5m
Fredun Medhora	MD, CFO & Whole Time Director	10.1yrs	₹5.40m	3.82% ₹ 121.0m
Jinkal Soni	Company Secretary & Compliance Officer	2.8yrs	₹300.00k	Veri yok

10.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 539730 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daulat Medhora	Executive Chairman & Joint MD	37.4yrs	₹1.20m	30.02% ₹ 950.5m
Fredun Medhora	MD, CFO & Whole Time Director	18.2yrs	₹5.40m	3.82% ₹ 121.0m
Nariman Medhora	Non-Executive Director	9.2yrs	Veri yok	15.32% ₹ 484.9m
Aspi Raimalwala	Non-Executive Independent Director	9.2yrs	₹112.00k	0.17% ₹ 5.4m
Rohinton Kanga	Non-Executive Independent Director	9.2yrs	₹112.00k	0.011% ₹ 336.8k
Daisy Dsouza	Non - Executive Independent Director	less than a year	₹16.00k	0.053% ₹ 1.7m

9.2yrs

Ortalama Görev Süresi

76yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 539730 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.2 yıldır).

Fredun Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director

Insufficient new directors

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Second quarter 2025 earnings released: EPS: ₹9.05 (vs ₹8.40 in 2Q 2024)

Fredun Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 26, 2024

Fredun Pharmaceuticals Limited announced that it expects to receive $10 million in funding from Amicorp Capital (Mauritius) Limited

Dividend of ₹0.70 announced

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹8.79 (vs ₹5.24 in 1Q 2024)

Fredun Pharmaceuticals Limited to Report Q1, 2025 Results on Jul 29, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Shareholder dilution

Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24

New major risk - Financial position

Full year 2024 earnings released: EPS: ₹33.32 (vs ₹24.13 in FY 2023)

Investor sentiment improves as stock rises 22%

Fredun Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 07, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 23%

Fredun Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director

Second quarter 2024 earnings released: EPS: ₹8.40 (vs ₹7.11 in 2Q 2023)

Fredun Pharmaceuticals Limited Proposes Dividend for the Financial Year Ended March 31, 2023

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director

First quarter 2024 earnings released: EPS: ₹5.24 (vs ₹2.12 in 1Q 2023)

Fredun Pharmaceuticals Limited to Report Q1, 2024 Results on Jul 19, 2023

Full year 2023 earnings released: EPS: ₹22.93 (vs ₹14.29 in FY 2022)

Fredun Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2022-23

Fredun Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023

Investor sentiment improves as stock rises 20%

Third quarter 2023 earnings released: EPS: ₹7.66 (vs ₹4.22 in 3Q 2022)

Fredun Pharmaceuticals Limited to Report Q3, 2023 Results on Jan 27, 2023

Insufficient new directors

Fredun Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 10, 2022

Investor sentiment improved over the past week

Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022

Fredun Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹2.12 (vs ₹0.82 in 1Q 2022)

Fredun Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 12, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year 2021-22

Fredun Pharmaceuticals Limited to Report Q4, 2022 Final Results on May 16, 2022

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Fredun Pharmaceuticals Limited Approves Appointment of Jinkal Shah as Company Secretary and Compliance Officer

Second quarter 2022 earnings released: EPS ₹4.61 (vs ₹2.07 in 2Q 2021)

Fredun Pharmaceuticals Limited announced that it expects to receive INR 106.119316 million in funding from Systematix Fincorp India Ltd, Subir Diamonds Pvt. Ltd and other investors

Investor sentiment improved over the past week

Upcoming dividend of ₹0.70 per share

Full year 2021 earnings released: EPS ₹5.05 (vs ₹4.77 in FY 2020)

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.55 in 3Q 2020)

New 90-day high: ₹514

Fredun Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹456

New 90-day high: ₹300

New 90-day high: ₹278

Fredun Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 09, 2020

Upcoming Dividend of ₹0.66 Per Share

Full year earnings released - EPS ₹4.77

Fredun Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 15, 2020

New 90-day high - ₹253

Fredun Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 29, 2020

New 90-day high - ₹207

CEO Tazminat Analizi